<?xml version='1.0' encoding='utf-8'?>
<document id="29307856"><sentence text="The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models." /><sentence text="Human Organic anion/cation transporters (OATs/OCTs), Organic anion transporting polypeptides (OATPs) and proton-coupled Oligopeptide transporters (PepTs) are important membrane transporters responsible of the cellular influx of drugs in many human key tissues" /><sentence text=" Inhibitor(s) impacting on the cellular uptake of transporter drug substrates is one of the primary causes of drug-drug interactions that lead to unsatisfied therapeutic outcomes and/or unwanted side effects" /><sentence text=" In the current study, we selected eighteen antibiotic agents used in infectious disease treatment and comprehensively evaluated their inhibitory effects on the substrate uptake mediated through the essential OATs/OCTs, OATPs and PepTs isoforms" /><sentence text=" Transport functional assay, dose-response curve and kinetic analysis were performed on the HEK293 cells over-expressing each of these transporter genes" /><sentence text=" Our data revealed that nitrofurantoin, sulfadiazine and metronidazole significantly inhibited the transport activity of OAT3 (IC50 values of 6"><entity charOffset="24-38" id="DDI-PubMed.29307856.s6.e0" text="nitrofurantoin" /><entity charOffset="40-52" id="DDI-PubMed.29307856.s6.e1" text="sulfadiazine" /><entity charOffset="57-70" id="DDI-PubMed.29307856.s6.e2" text="metronidazole" /><pair ddi="false" e1="DDI-PubMed.29307856.s6.e0" e2="DDI-PubMed.29307856.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29307856.s6.e0" e2="DDI-PubMed.29307856.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29307856.s6.e0" e2="DDI-PubMed.29307856.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29307856.s6.e1" e2="DDI-PubMed.29307856.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29307856.s6.e1" e2="DDI-PubMed.29307856.s6.e2" /></sentence><sentence text="23±1" /><sentence text="33μM, 6" /><sentence text="65±1" /><sentence text="30μM and 6" /><sentence text="51±0" /><sentence text="99μM; Ki values of 5" /><sentence text="86μM, 3" /><sentence text="98μM and 6" /><sentence text="48μM, respectively)" /><sentence text=" Trimethoprim and ciprofloxacin potently decreased the substrate uptake mediated via OATP1A2 (IC50 values of 9"><entity charOffset="1-13" id="DDI-PubMed.29307856.s16.e0" text="Trimethoprim" /><entity charOffset="18-31" id="DDI-PubMed.29307856.s16.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.29307856.s16.e0" e2="DDI-PubMed.29307856.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29307856.s16.e0" e2="DDI-PubMed.29307856.s16.e1" /></sentence><sentence text="35±1" /><sentence text="10μM and 9" /><sentence text="25±1" /><sentence text="18μM; Ki values of 8" /><sentence text="19μM and 7" /><sentence text="64μM, respectively)" /><sentence text=" In addition, these antibiotic agents consistently decreased methotrexate influx via OAT3 and OATP1A2"><entity charOffset="61-73" id="DDI-PubMed.29307856.s23.e0" text="methotrexate" /></sentence><sentence text=" In summary, our study is the first to show that nitrofurantoin, sulfadiazine and metronidazole are potent inhibitors of OAT3 and trimethoprim is a novel inhibitor of OATP1A2"><entity charOffset="49-63" id="DDI-PubMed.29307856.s24.e0" text="nitrofurantoin" /><entity charOffset="65-77" id="DDI-PubMed.29307856.s24.e1" text="sulfadiazine" /><entity charOffset="82-95" id="DDI-PubMed.29307856.s24.e2" text="metronidazole" /><entity charOffset="121-125" id="DDI-PubMed.29307856.s24.e3" text="OAT3" /><entity charOffset="130-142" id="DDI-PubMed.29307856.s24.e4" text="trimethoprim" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e0" e2="DDI-PubMed.29307856.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e0" e2="DDI-PubMed.29307856.s24.e1" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e0" e2="DDI-PubMed.29307856.s24.e2" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e0" e2="DDI-PubMed.29307856.s24.e3" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e0" e2="DDI-PubMed.29307856.s24.e4" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e1" e2="DDI-PubMed.29307856.s24.e1" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e1" e2="DDI-PubMed.29307856.s24.e2" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e1" e2="DDI-PubMed.29307856.s24.e3" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e1" e2="DDI-PubMed.29307856.s24.e4" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e2" e2="DDI-PubMed.29307856.s24.e2" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e2" e2="DDI-PubMed.29307856.s24.e3" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e2" e2="DDI-PubMed.29307856.s24.e4" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e3" e2="DDI-PubMed.29307856.s24.e3" /><pair ddi="false" e1="DDI-PubMed.29307856.s24.e3" e2="DDI-PubMed.29307856.s24.e4" /></sentence><sentence text=" Our study also provides new evidence for the drug-drug interactions of ciprofloxacin with OATP1A2 drug substrates like methotrexate"><entity charOffset="72-85" id="DDI-PubMed.29307856.s25.e0" text="ciprofloxacin" /><entity charOffset="120-132" id="DDI-PubMed.29307856.s25.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.29307856.s25.e0" e2="DDI-PubMed.29307856.s25.e0" /><pair ddi="false" e1="DDI-PubMed.29307856.s25.e0" e2="DDI-PubMed.29307856.s25.e1" /></sentence><sentence text=" Therefore, precautions are required when co-administering these antibiotics with OAT3 or OATP1A2 drug substrates"><entity charOffset="82-93" id="DDI-PubMed.29307856.s26.e0" text="OAT3" /></sentence><sentence text="" /></document>